Research
55.4% of patients in the ketamine group exhibited a significant reduction in depressive symptoms. In comparison, 41.2% of patients undergoing...
While yet another study shows psilocybin's efficacy in treating depression in cancer patients, and 2024 presidential candidates push for a...
As MDMA nears FDA approval, LSD's efficacy in treating generalized anxiety disorder is demonstrated in MindMed's Phase 2b study. Meanwhile,...
2023 psychedelic research shows optimal psilocybin dose for depression and the efficacy of psilocybin to treat depression....
The FDA will have 60 days "to determine whether the MDMA-AT NDA application will be accepted for review and whether...
One possible reason for this phenomenon is psilocybin’s interaction with the thalamus, the section of our brain that receives sensory...
The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two...
Classic psychedelics might effectively kill pain with even greater vigor over time, sharply contrasting with opioids....
Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a "both and" approach to...
A new study exploring real-world psychedelic microdosing for ADHD could help reimagine the way we perceive and treat the condition....